

SIERRA LEONE

Support for Pneumococcal Conjugate Vaccine

This Decision Letter sets out the Programme Terms of a Programme

1. Country:	Sierra Leone						
2. Vaccine grant number:	09-SLE-8b-Y, 1215-SLE-12C-X, 16-SLE-12c-X, 17-SLE-12c-X, 18-SLE-25a-Y, 1821-SLE-12d-X						
3. Date of Decision Letter:	30-Sep-2019						
4. Date of the Partnership Framework Agreement:	3/10/2013						
5. Programme title:	New Vaccine Support (NVS), Pneumococcal , Routine						
6. Vaccine type:	Pneumococcal Conjugate Vaccine						
7. Requested product presentation and formulation of vaccine:	PCV13, 4 doses per vial, LIQUID						
8. Programme Duration:¹	2010-2021						
9. Programme Budget (indicative):²	(subject to the terms of the Partnership Framework Agreement, if applicable)						
	2010-2019	2020	2021	2022	2023	2024	Total²
Programme Budget (US\$)	28,377,085	540,000	1,834,500	-	-	-	30,827,976
10. Vaccine introduction grant							
	Approval						
	Year	Grant Number	Amount (US\$)				
	2009	09-SLE-8b-Y	100,000				
	Disbursement						
	Disbursement date		Amount (US\$)				
	28 May, 2010		100,000				
11. Product switch grant							
	Approval						
	Year	Grant Number	Amount (US\$)				
	2018	18-SLE-25a-Y	75,533				
	Disbursement						
	Disbursement date		Amount (US\$)				
	25 February, 2019		75,467				
12. Indicative Annual Amounts:³	(subject to the terms of the Partnership Framework Agreement, if applicable)						

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme.

³ This is the amount that Gavi has approved.

Type of supplies to be purchased with Gavi funds	2010-2019	2020	2021
Number of vaccine doses		167,600	-
Annual Amounts (US\$)	28,377,085	540,000	-

13. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.

14. Self-procurement: Not applicable

15. Co-financing obligations:

According to the co-financing policy, the Country falls within the group: Initial self-financing

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2020	2021	2022	2023	2024
Number of vaccine doses	38,000	45,800	-	-	-
Number of AD syringes	-	-	-	-	-
Number of re-constitution syringes	-	-	-	-	-
Number of safety boxes	-	-	-	-	-
Value of vaccine doses (US\$)	109,821	132,493	-	-	-
Total co-financing payments (US\$) (including freight)	111,500	134,500	-	-	-

16. Operational support for campaigns:
Not applicable

17. Additional Reporting Requirements:

	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> Vaccine stock levels including buffer stock Number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received Country shall report the actual switch date in the first renewal request following the actual implementation. 	31 March 2020 15 May 2020

In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat
18. Financial clarifications:	Not applicable

Signed by,

On behalf of Gavi



Thabani Maphosa
Managing Director, Country Programmes
30-Sep-2019